SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):May 24, 2010

 

Abbott Laboratories

(Exact Name of Registrant as Specified in its Charter)

 

Illinois

(State or Other Jurisdiction of Incorporation)

 

 

 

(847) 937-6100

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 1.01                                             Entry Into a Material Definitive Agreement

 

Abbott Laboratories (“Abbott”) entered into an Underwriting Agreement, dated as of May 24, 2010 (the “Underwriting Agreement”), and a Pricing Agreement, dated as of May 24, 2010 (the “Pricing Agreement”), by and between Abbott and Banc of America Securities LLC, J.P. Morgan Securities Inc., Morgan Stanley & Co. Incorporated, Barclays Capital Inc. and Deutsche Bank Securities Inc., as representatives of the several underwriters named on Schedule I to the Pricing Agreement (the “Underwriters”), pursuant to which Abbott has agreed to issue to the Underwriters $750,000,000 aggregate principal amount of senior 2.700% Notes due May 27, 2015 (the “2015 Notes”), $1,000,000,000 aggregate principal amount of senior 4.125% Notes due May 27, 2020 (the “2020 Notes”) and $1,250,000,000 aggregate principal amount of senior 5.300% Notes due May 27, 2040 (the “2040 Notes,” and together with the 2015 Notes and the 2020 Notes, the “Debt Securities”). Each series of the Debt Securities is subject to the Registration Statement on Form S-3 (File No. 333-157290) that Abbott filed with the Securities and Exchange Commission (the “SEC”) on February 12, 2009 relating to the public offering from time to time of debt securities of Abbott pursuant to Rule 415 of the Securities Act of 1933, as amended. In connection with Abbott’s filing with the SEC of a definitive prospectus supplement, dated May 24, 2010, and prospectus, dated February 12, 2009, relating to the public offering of the Debt Securities, Abbott is filing certain exhibits as part of this Current Report on Form 8-K. See “Item 9.01 - Financial Statements and Exhibits.”

 

Item 9.01               Financial Statements and Exhibits

 

(d) Exhibits

 

99.1		Underwriting Agreement
99.2		Pricing Agreement
99.3		Actions of the Authorized Officers (Exhibits A-1, A-2, A-3 and B to Exhibit 99.3 are filed as Exhibits 99.4, 99.5, 99.6 and 99.2, respectively, to this Form 8-K)
99.4		Form of 2015 Note
99.5		Form of 2020 Note
99.6		Form of 2040 Note
99.7		Opinion of Mayer Brown LLP
99.8		Consent of Mayer Brown LLP (included in Exhibit 99.7 hereto)

 

1

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Abbott Laboratories
May 27, 2010	By:	/s/ Thomas C. Freyman
		Name:	Thomas C. Freyman
		Title:	Executive Vice President, Finance and Chief Financial Officer

 

2

 

EXHIBIT INDEX

 

Exhibit No.		Exhibit
99.1		Underwriting Agreement
99.2		Pricing Agreement
99.3		Actions of the Authorized Officers (Exhibits A-1, A-2, A-3 and B to Exhibit 99.3 are filed as Exhibits 99.4, 99.5, 99.6 and 99.2, respectively, to this Form 8-K)
99.4		Form of 2015 Note
99.5		Form of 2020 Note
99.6		Form of 2040 Note
99.7		Opinion of Mayer Brown LLP
99.8		Consent of Mayer Brown LLP (included in Exhibit 99.7 hereto)

 

3